The Academy of Managed Care Pharmacy recently installed 4 new members to its board of directors. The new board members were sworn in April 29 at AMCP?s 23rd Annual Meeting & Showcase in Minneapolis.
The Academy of Managed Care Pharmacy (AMCP) recently installed 4 new members to its board of directors. The new board members were sworn in April 29 at AMCP’s 23rd Annual Meeting & Showcase in Minneapolis.
Doug Burgoyne, president-elect and a board member for the past 2 years, is president of VRX Pharmacy Services. Prior to this position, Burgoyne served on 3 committees-Legislative, Membership, and Program Planning and Development, where he served as committee chair. He believes the most compelling managed care issues over the next 5 years are healthcare reform and successfully managing high-cost specialty drugs, including follow-on biologics.
“Managed care pharmacists will need to collaborate with other providers and creatively develop management strategies that maintain affordability of care in a new world,” Burgoyne said.
Robert Gregory, treasurer, is pharmacy director for Aetna Pharmacy Management. He has more than 30 years of experience as a practicing pharmacist and healthcare manager. Gregory seeks to promote diversity and inclusion throughout AMCP.
“Leadership and staff must continue to search out additional opportunities whether they be selling services or developing additional products,” Gregory said. “It must be able to leverage the diversity of members and the strength of the brand with key external markets and communities.”
Steven G. Avey, board of director, is vice president of national sales, RegenceRx. He served 5 years as the executive director of the Foundation for Managed Care Pharmacy. Avey believes the most compelling factor facing managed care pharmacy over the next 5 years is the large influx of insured Americans being enrolled in government programs.
“Managed care pharmacists will be asked to ensure that each health plan or PBM is paying for the most appropriate medication from a clinical and cost perspective,” Avey said.
H. Eric Cannon, board of director, is chief of pharmacy services at SelectHealth, an Intermountain Healthcare Company. He was vice chair of the AMCP Organizational Affairs Committee, and served on the Legislative Committee as both a member and chair.
Cannon said AMCP has a responsibility to help and provide counsel during the implementation of the Accountable Care Act. “Health reform will touch all of the members of AMCP in one way or another,” Cannon added. “All of the AMCP membership will be affected by the guidelines and standards set in place by the federal government.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.